Close Menu

NEW YORK (GenomeWeb) – Quidel reported after the close of the market on Monday that its first quarter revenues rose 46 percent year over year, thanks largely to higher sales of immunoassay, molecular, and specialty products.

For the three months ended March 31, revenues rose to $73.7 million from $50.3 million in Q1 2016, and beat the average analysts' estimate of $62.0 million.

The firm said that influenza revenues rose 112 percent to $40.8 million year over year, thanks to a severe and longer-than-usual respiratory disease season.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

Nobel laureates and scientific societies urge NIH and the Department of Health and Human Services to revisit the recent decision to end funding for a coronavirus grant.

Bloomberg reports that BGI's SARS-CoV-2 testing sites in the Middle East have raised concerns among US officials.

A new Pew Research Center poll finds confidence in medical researchers has grown among US adults since the start of the coronavirus pandemic.

In Science this week: machine learning algorithm for faster Mendelian disorder diagnoses, gene linked to safe response to nitrogen-containing bisphosphonates, and more.